Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (401-410 of 418) with videos related to

Pageof 42
Sort By:
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialPetros Grivas, Elena Garralda, Funda Meric-Bernstam, et al.
Nature|July 8, 2016
Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
The Lancet. Oncology|February 17, 2018
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L McQuade, Carrie R Daniel, Kenneth R Hess, et al.
Nature|April 5, 2016
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
Science (New York, N.Y.)|September 16, 2017
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabineLeore T Geller, Michal Barzily-Rokni, Tal Danino, et al.
Nature|October 30, 2025
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
Cancer Research|August 31, 2021
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy ResistanceJianglan Liu, Vito W Rebecca, Andrew V Kossenkov, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapyOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.
Pageof 42

Showing results (401-410 of 418) with videos related to

Sort By:
Pageof 42
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialPetros Grivas, Elena Garralda, Funda Meric-Bernstam, et al.
Nature|July 8, 2016
Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
The Lancet. Oncology|February 17, 2018
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L McQuade, Carrie R Daniel, Kenneth R Hess, et al.
Nature|April 5, 2016
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
Science (New York, N.Y.)|September 16, 2017
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabineLeore T Geller, Michal Barzily-Rokni, Tal Danino, et al.
Nature|October 30, 2025
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
Cancer Research|August 31, 2021
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy ResistanceJianglan Liu, Vito W Rebecca, Andrew V Kossenkov, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapyOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.
Pageof 42